About

The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and the University of British Columbia and tested and refined on approximately 1,000 lesions at the Skin Care Centre at Vancouver General Hospital.

Verisante Technology Inc. (VRS.V)
Last Traded
1:07pm - 0.015
Volume
16,000
Open
0.02
Previous Close
0.02
Bid
0.02
Ask
0.02
Bid Size
N/A
Ask Size
N/A
Market Cap
1.43M
Shares Owned
N/A
Peg Ratio
0.000
Dividend Yield
N/A
Events & Conferences